Lead Heart Trial Beats Faster for Mesoblast; Interim Analysis Encouraging
We are raising our fair value estimate to AUD 2.80 per share from AUD 2.30 for no-moat Mesoblast Ltd (MSB AU), following the encouraging interim...
143 Views
US Healthcare Overhaul Stumbling, Singapore Cyclical Rally Looking Premature
The Republican replacement for ‘Obamacare’ has been announced and looks an incoherent mess – resurgent healthcare inflation will be a drag on...
1.6k Views
AI & Machine Learning Disrupting The Healthcare Industry
In the omnipresence of machine learning, one of the most impacted segments is healthcare. Not only is AI in healthcare at the forefront of a...
600 Views
A Storm Will Follow the Lull
Newsflow around the US and state governments' antitrust investigations of the generic drug industry has been quiet since mid-December. Some lull is...
722 Views
Trump Health Effect: What Is Next for the Consumer Health Industry Under Trump's Leadership?
While the US consumer health industry will remain a strong centre for investment, development and technology innovation in 2017 and is expected to...
3.2k Views